Alessandro Galbiati

Alessandro Galbiati

Auto-generated profile, based on publicly available information

Alessandro Galbiati

Artios Pharma, Cambridge, United Kingdom

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 January 2023 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
GRGonzalo Rodriguez-Berriguete
Gonzalo Rodriguez-Berriguete
MRMarco Ranzani
Marco Ranzani
RPRemko Prevo
Remko Prevo
RPRathi Puliyadi
Rathi Puliyadi
NMNicole Machado
Nicole Machado
GHGeoff S. Higgins
Geoff S. Higgins
Purpose: DNA polymerase theta (Polθ, encoded by the POLQ gene) is a DNA repair enzyme critical for microhomology mediated end joining (MMEJ). Polθ has limited expression in normal tissues but is frequently overexpressed in cancer cells and, therefore, represents an ideal target for tumor-specific radiosensitization. In this study we evaluate whether targeting Polθ with novel small-molecule inhibitors is a feasible strategy to improve the efficacy of radiotherapy. Experimental Design: We characterized the response to Polθ inhibition in combination with ionizing radiation in different cancer cell models in vitro and in vivo. Results: Here, we show that ART558 and ART899, two novel and specific allosteric inhibitors of the Polθ DNA polymerase domain, potently radiosensitize tumor cells, particularly when combined with fractionated radiation. Importantly, noncancerous cells were not radiosensitized by Polθ inhibition. Mechanistically, we show that the radiosensitization caused by Polθ inhibition is most effective in replicating cells and is due to impaired DNA damage repair. We also show that radiosensitization is still effective under hypoxia, suggesting that these inhibitors may help overcome hypoxia-induced radioresistance. In addition, we describe for the first time ART899 and characterize it as a potent and specific Polθ inhibitor with improved metabolic stability. In vivo, the combination of Polθ inhibition using ART899 with fractionated radiation is well tolerated and results in a significant reduction in tumor growth compared with radiation alone. Conclusions: These results pave the way for future clinical trials of Polθ inhibitors in combination with radiotherapy.

6 October 2022 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MSMartin L. Stockley
Martin L. Stockley
AFAmanda Ferdinand
Amanda Ferdinand
GBGiovanni Benedetti
Giovanni Benedetti
PBPeter Blencowe
Peter Blencowe
SBSusan M. Boyd
Susan M. Boyd
RHRobert A. Heald
Robert A. Heald

21 October 2022 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
KJKunzah Jamal
Kunzah Jamal
AGAlessandro Galbiati
Alessandro Galbiati
JAJoshua Armenia
Joshua Armenia
GIGiuditta Illuzzi
Giuditta Illuzzi
JHJames Hall
James Hall
JFJosep V Forment
Josep V Forment
PARP inhibitors (PARPi) are currently indicated for the treatment of ovarian, breast, pancreatic, and prostate cancers harboring mutations in the tumor suppressor genes BRCA1 or BRCA2. In the case of ovarian and prostate cancers, their classification as homologous recombination repair (HRR) deficient (HRD) or mutated also makes PARPi an available treatment option beyond BRCA1 or BRCA2 mutational status. However, identification of the most relevant genetic alterations driving the HRD phenotype has proven difficult and recent data have shown that other genetic alterations not affecting HRR are also capable of driving PARPi responses. To gain insight into the genetics driving PARPi sensitivity, we performed CRISPR-Cas9 loss-of-function screens in six PARPi-insensitive cell lines and combined the output with published PARPi datasets from eight additional cell lines. Ensuing exploration of the data identified 110 genes whose inactivation is strongly linked to sensitivity to PARPi. Parallel cell line generation of isogenic gene knockouts in ovarian and prostate cancer cell lines identified that inactivation of core HRR factors is required for driving in vitro PARPi responses comparable with the ones observed for BRCA1 or BRCA2 mutations. Moreover, pan-cancer genetic, transcriptomic, and epigenetic data analyses of these 110 genes highlight the ones most frequently inactivated in tumors, making this study a valuable resource for prospective identification of potential PARPi-responsive patient populations. Importantly, our investigations uncover XRCC3 gene silencing as a potential new prognostic biomarker of PARPi sensitivity in prostate cancer.Significance: This study identifies tumor genetic backgrounds where to expand the use of PARPis beyond mutations in BRCA1 or BRCA2. This is achieved by combining the output of unbiased genome-wide loss-of-function CRISPR-Cas9 genetic screens with bioinformatics analysis of biallelic losses of the identified genes in public tumor datasets, unveiling loss of the DNA repair gene XRCC3 as a potential biomarker of PARPi sensitivity in prostate cancer.

18 December 2023 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
EREeson Rajendra
Eeson Rajendra
DGDiego Grande
Diego Grande
BMBethany Mason
Bethany Mason
DMDaniela Di Marcantonio
Daniela Di Marcantonio
LALucy Armstrong
Lucy Armstrong
HRHelen M R Robinson
Helen M R Robinson
Repair of DNA damage is essential for the maintenance of genome stability and cell viability. DNA double strand breaks (DSBs) constitute a toxic class of DNA lesion and multiple cellular pathways exist to mediate their repair. Robust and titratable assays of cellular DSB repair (DSBR) are important to functionally interrogate the integrity and efficiency of these mechanisms in disease models as well as in response to genetic or pharmacological perturbations. Several variants of DSBR reporters are available, however these are often limited by throughput or restricted to specific cellular models. Here, we describe the generation and validation of a suite of extrachromosomal reporter assays that can efficiently measure the major DSBR pathways of homologous recombination (HR), classical nonhomologous end joining (cNHEJ), microhomology-mediated end joining (MMEJ) and single strand annealing (SSA). We demonstrate that these assays can be adapted to a high-throughput screening format and that they are sensitive to pharmacological modulation, thus providing mechanistic and quantitative insights into compound potency, selectivity, and on-target specificity. We propose that these reporter assays can serve as tools to dissect the interplay of DSBR pathway networks in cells and will have broad implications for studies of DSBR mechanisms in basic research and drug discovery.

26 November 2025
Verified
Journal Article
Open access
EREeson Rajendra
Eeson Rajendra
CLClaudio A Lademann
Claudio A Lademann
BMBethany Mason
Bethany Mason
BMBalca R Mardin
Balca R Mardin
LALucy Armstrong
Lucy Armstrong
LBLars T Burgdorf
Lars T Burgdorf
Flap endonuclease 1 (FEN1) is a structure-specific nuclease with critical functions in DNA replication and repair. FEN1 has been proposed as an anti-cancer drug target because of its synthetic lethal interaction with homologous recombination deficiency (HRD). However, the exploration of FEN1 in this context has been hampered by the lack of suitable small molecule tools. Here, we describe MSC778, a highly potent, specific and selective small molecule inhibitor of FEN1 nuclease activity. MSC778 directly engages FEN1 in cells, enhances its retention on chromatin, and selectively kills BRCA-deficient cells. Mechanistically, MSC778 suppresses DNA replication causing S-phase accumulation, DNA damage, and ultimately, cell death. Cancer cell panel screening identified Ewing sarcoma (EWS) cells as sensitive to MSC778, which is driven by the expression of SLFN11. In addition to HRD, CRISPR screening revealed a spectrum of synthetic lethal interactions between MSC778 and DNA damage response (DDR) factors, such as PARP1, USP1, PARG, and ATR. Furthermore, we demonstrate that combined inhibition of these factors with MSC778 induces synergistic killing of cancer cells. Together these data highlight FEN1 inhibition as an attractive precision oncology strategy either as monotherapy or as a combination therapy with a broad range of current and next generation DDR-targeting agents.

13 July 2026 in Clinical Cancer Research
Verified
Journal Article
Open access
HRHelen M.R. Robinson
Helen M.R. Robinson
VGVera Grinkevich
Vera Grinkevich
JMJayesh B. Majithiya
Jayesh B. Majithiya
SMSam E. Mann
Sam E. Mann
CMClaire McWhirter
Claire McWhirter
GSGraeme C.M. Smith
Graeme C.M. Smith
Purpose: DNA polymerase theta (Polθ) is the central component of DNA double-strand break repair through microhomology-mediated end joining (MMEJ). Targeting Polθ for cancer therapy has been proposed due to its tumor-selective expression, as well as its role in the survival of homologous recombination–deficient (HRD) cancer cells. Additionally, inhibition of Polθ has been shown to potentiate the effects of DNA damage, such as that caused by poly (ADP-ribose) polymerase (PARP) inhibition. In this study, we present the pharmacologic profile of ART6043, a potent, selective, allosteric, small-molecule inhibitor of the polymerase function of Polθ. Experimental Design: A series of in vitro studies were performed to demonstrate the biochemical and cellular on-target activity of ART6043 in relevant model systems, focusing on combination with PARP inhibitors. Subsequent in vivo studies established a pharmacokinetic/pharmacodynamic/efficacy relationship and explored ART6043’s ability to potentiate the efficacy of PARP inhibitors across a range of cell line-derived xenograft (CDX), patient-derived xenograft (PDX), and genetically engineered mouse models of HRD tumors. Results: ART6043 inhibits Polθ with low nmol/L potency and specifically abrogates MMEJ in cells. Additionally, ART6043 inhibits the survival of HRD cells and potentiates the efficacy of PARP inhibitors in vitro. Furthermore, ART6043 has excellent pharmaceutical properties, is well tolerated, and induces tumor regressions in combination with PARP inhibitors in vivo in HRD models. Conclusions: The data demonstrate strong potential for ART6043 as an anticancer therapeutic for HRD tumors in combination with PARP inhibitors. Based on this, combination therapy of ART6043 with PARP inhibitor treatment is being tested in an ongoing phase I/IIa clinical trial (NCT05898399).